AVVA Pharmaceuticals Ltd announces a new phase III clinical trial plan for Ecoclav.
Ecoclav belongs to a new class of antibiotics that address common medical needs, and concerns that to date were thought to be acceptable. The project focuses on the development of a friendlier antibiotic, in respect to the human microecology and its impact on metabolic processes and the immune system.
Ecoclav is the analog of the commonly referred antibiotic Co-amoxiclav, a broad-spectrum antibiotic consisting of a b-lactam antibiotic and a b-lactamase inhibitor.
The broad use and importance of this medication is evident from its inclusion in the World health Organization’s (WHO) list of Essential Medicines. Co-Amoxiclav is the number one (1) used antibiotic worldwide.